GABA A α5 PAM Discovery
Spectrum of neurological/psychiatric conditions (e.g., MCI due to AD, schizophrenia)
Key Facts
About AgeneBio
AgeneBio is a private, pre-revenue biotech founded in 2010 and headquartered in Indianapolis, Indiana. The company is advancing a novel therapeutic approach targeting neural overactivity to prevent Alzheimer's dementia, with its lead asset, AGB101, in a pivotal Phase 2b/3 trial for amnestic Mild Cognitive Impairment (MCI) due to Alzheimer's disease. Led by founder and CEO Dr. Michela Gallagher, a renowned neuroscientist from Johns Hopkins University, the company leverages deep scientific expertise and a management team with proven drug development experience. AgeneBio operates in a high-need, high-value market with no currently approved treatments for its lead indication.
View full company profile